Cardiovascular risk factors in patients with chronic kidney disease

Nature Reviews Cardiology

Volumn 6, Issue 9, 2009, Pages 580-589

  Vander Zee, Sarina ^a   Baber, Usman ^a   Elmariah, Sammy ^a   Winston, Jonathan ^b   Fuster, Valentin ^a  

^a The Zena and Michael A wiener Cardiovascular institute and Marie Josée and Henry R Kravis Cardiovascular Health Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TIME;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 70350739118     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.121     Document Type: Review

References (94)

1. Go, A. S., Chertow, G. M., Fan, D., Factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 16, 529-538 (2005).
2. Manjunath, G. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J.Am. Coll. Cardiol. 41, 47-55 (2003).
3. Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular McCulloch, C. E. and Hsu, C. Y Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004).
4. Shlipak, M. G. et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 62, 997-1004 (2002).
5. Muntner, P, He, J., Astor, B. C., Folsom, A. R. and Coresh, J. Traditional and nontraditional risk disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169 (2003).
6. Vassalotti, J. A., Stevens, L. A. and Levey, A. S. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am. J. Kidney Dis. 50, 169-180 (2007).
7. Brosius, F. C. et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes research interdisciplinary working Group: Developed in Collaboration with the National Kidney Foundation. Hypertension 48, 751-755 (2006).
8. Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737-1745 (2005).
9. Baber, U. et al. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 73, 615-621 (2008).
10. Parikh, N. I. et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 166, 1884-1891 (2006).
11. Shoji, T. et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 61, 2187-2192 (2002).
12. Flack, J. M., Neaton, J. D., Daniels, B. and Esunge, P. Ethnicity and renal disease: lessons from the Multiple Risk Factor intervention Trial and the Treatment of Mild Hypertension Study. Am. J. Kidney Dis. 21 (Suppl. 1), 31-40 (1993).
13. weiner, D. E. et al. The Framingham predictive instrument in chronic kidney disease. J. Am. Coll. Cardiol. 50, 217-224 (2007).
14. weiner, D. E. et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am. J. Kidney Dis. 51, 212-223 (2008).
15. Cheung, A. K. et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 58, 353-362 (2000).
16. Zager, F. G. et al. ‘U’ curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, inc. Kidney Int. 54, 561-569 (1998).
17. Cooper, S. P. et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am. J. Epidemiol. 127, 387-403 (1988).
18. Liu, Y. et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291, 451-459 (2004).
19. Kilpatrick, R. D. et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J. Am. Soc. Nephrol. 18, 293-303 (2007).
20. Stidley, C. A. et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J. Am. Soc. Nephrol. 17, 513-520 (2006).
21. Udayaraj, U. P et al. Blood pressure and mortality risk on peritoneal dialysis. Am. J. Kidney Dis. 53, 70-78 (2009).
22. Jamison, R. L. et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163-1170 (2007).
23. Jamison, R. L. et al. Kidney Disease Outcomes Quality initiative (K/DOQi) Group. K/DOQi clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41 (Suppl. 3), 1-91 (2003).
24. Jamison, R. L. et al. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel iii) final report. Circulation 106, 3143-3421 (2002).
25. Harper, C. R. and Jacobson, T. A. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51, 2375-2384 (2008).
26. Harper, C. R. and Jacobson, T. A. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol National Kidney Foundation. K/DOQi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39 (Suppl. 1), 1-266 (2002).
27. Fox, C. S. et al. Predictors of new-onset kidney disease in a community-based population. JAMA 291, 844-850 (2004).
28. King, H., Aubert, R. E. and Herman, W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431 (1998).
29. Greenlund, K. J. et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch. Intern. Med. 164, 181-188 (2004).
30. Coresh, J. et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047 (2007).
31. Coresh, J. et al. United State Renal Data System [online], http://www.usrds.org/2008/view/esrd 11.asp (2008). The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US government.
32. Mann, J. F., Gerstein, H. C., Pogue, J., Bosch, J. and Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2001).
33. weiner, D. E. et al. Chronic kidney disease as a risk factor for cardiovascular disease and allcause mortality: a pooled analysis of community- based studies. J. Am. Soc. Nephrol. 15, 1307-1315 (2004).
34. McCullough, P. A. et al. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch. Intern. Med. 167, 1122-1129 (2007).
35. Culleton, B. F. et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56, 2214-2219 (1999).
36. Dries, D. L. et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J.Am. Coll. Cardiol. 35, 681-689 (2000).
37. Fried, L. F. et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J. Am. Coll. Cardiol. 41, 1364-1372 (2003).
38. Foley, R. N., Parfrey, P. S. and Sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32 (Suppl. 3), S112-S119 (1998).
39. Elsayed, E. F. et al. Cardiovascular disease and subsequent kidney disease. Arch. Intern. Med. 167, 1130-1136 (2007).
40. Elsayed, E. F. et al. Lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
41. Tonelli, M. et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110, 1557-1563.
42. Shepherd, J. et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J. Am. Coll. Cardiol. 51, 1448-1454 (2008).
43. Asselbergs, F. W. et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110, 2809-2816 (2004).
44. Nishizawa, Y., Shoji, T., ishimura, E., inaba, M. and Morii, H. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am. J. Kidney Dis. 38 (Suppl. 1), S4-S7 (2001).
45. Seliger, S. L. et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 61, 297-304 (2002).
46. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248.
47. Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
48. Davidson, M. H., Armani, A., McKenney, J. M. and Jacobson, T. A. Safety considerations with fibrate therapy. Am. J. Cardiol. 99, 3C-18C (2007).
49. Goldfarb-Rumyantzev, A. S., Habib, A. N., Baird, B. C., Barenbaum, L. L. and Cheung, A. K. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am. J. Kidney Dis. 50, 791-802 (2007).
50. Siamopoulos, K. C. et al. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit. Dial. Int. 15, 342-347 (1995).
51. Xue, J. L. et al. Peritoneal and hemodialysis: Differences in patient characteristics at initiation. Kidney Int. 61, 734-740 (2002).
52. Agodoa, L. Y et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285, 2719-2728 (2001).
53. Wright, J. T. Jr et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288, 2421-2431 (2002).
54. Klahr, S. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330, 877-884 (1994).
55. Ruilope, L. M. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 12, 218-225 (2001).
56. Sarnak, M. J. et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann. Intern. Med. 142, 342-351 (2005).
57. Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
58. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
59. Brenner, B. M. et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MiCRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study investigators. Lancet 355, 253-259 (2000).
60. Agrawal, V, Marinescu, V., Agarwal, M. and McCullough, P A. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat. Rev. Cardiol. 6, 301-311 (2009).
61. Jafar, T H. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 135, 73-87 (2001).
62. Johnson, D. W., Craven, A. M. and isbel, N. M. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial. Int. 11, 1-14 (2007).
63. Kalantar-Zadeh, K., Block, G., Humphreys, M. H. and Kopple, J. D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 63, 793-808 (2003).
64. Vlagopoulos, P T et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J. Am. Soc. Nephrol. 16, 3403-3410 (2005).
65. Foley, R. N. et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in endstage renal disease. Kidney Int. 49, 1379-1385 (1996).
66. Zannad, F. et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 70, 1318-1324 (2006).
67. Heerspink, H. J. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373, 1009-1015 (2009).
68. Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. and Port, F. K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31, 607-617 (1998).
69. St Peter, W. L., Liu, J., Weinhandl, E. and Fan, Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis. 51, 445-54 (2008).
70. Suki, W. N. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 72, 1130-1137 (2007).
71. Chertow, G. M., Burke, S. K. and Raggi, P., Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62, 245-252 (2002).
72. Raggi, P and Kleerekoper, M., Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 836-843 (2008).
73. Teng, M. et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16, 1115-1125.
74. Teng, M. et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349, 446-456 (2003).
75. Tentori, F. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858-1865.
76. Palmer, S. C. et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann. Intern. Med. 147, 840-853 (2007).
77. Boaz, M. et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356, 1213-1218 (2000).
78. Mann, J. F. et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int. 65, 1375-1380 (2004).
79. Tepel, M., van der Giet, M., Statz, M., Jankowski, J. and Zidek, W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107, 992-995 (2003).
80. Wrone, E. M. et al. Randomized trial of folic acid for prevention of cardiovascular events in endstage renal disease. J. Am. Soc. Nephrol. 15, 420-426 (2004).
81. Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006).
82. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006).
83. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998).
84. Fleischmann, E. H., Bower, J. D. and Salahudeen, A. K. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients. Clin. Nephrol. 56, 221-230 (2001).
85. Becker, B. N., Himmelfarb, J., Henrich, W. L. and Hakim, R. M. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J. Am. Soc. Nephrol. 8, 475-486 (1997).
86. Takeda, A. et al. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am. J. Kidney Dis. 45, 112-118 (2005).
87. Herzog, C. A., Littrell, K., Arko, C., Frederick, P D. and Blaney, M. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial infarction. Circulation 116, 1465-1472 (2007).
88. Wright, R. S. et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. 137, 563-570 (2002).
89. Patel, U. D. et al. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am. J. Kidney Dis. 53, 426-37 (2009).
90. Goldberg, R. J., ismailov, R. M., Patlolla, V., Lessard, D. and Spencer, F. A. Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective. Am. J. Kidney Dis. 51, 594-602 (2008).
91. Winkelmayer, W. C., Levin, R. and Setoguchi, S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin. J. Am. Soc. Nephrol. 3, 1415-1422 (2008).
92. Manjunath, G. et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 63, 1121-1129 (2003).
93. Tonelli, M., Moye, L., Sacks, F. M., Kiberd, B. and Curhan, G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann. Intern. Med. 138, 98-104 (2003).
94. Andreucci, V. E. et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am. J. Kidney Dis. 44, 61-67 (2004).